Current clinical trials of incretin-based treatments for mental health conditions

Incretin-based therapies are being repurposed for psychiatric disorders.

• Conventional glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1-containing co-agonists are under consideration for new uses.
• The current pipeline for randomized trials may be broader and more advanced than it appears.
• There is potential for these therapies to impact psychiatric conditions, although specific outcomes are not detailed.

Simplified